Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gene therapy becomes...

    Gene therapy becomes reality, but at a price tag of 1 million dollar

    Written by Ruby Khatun Khatun Published On 2017-11-20T09:45:48+05:30  |  Updated On 18 Aug 2021 12:25 PM IST

    LONDON: Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers.


    Spark Therapeutics, whose Luxturna treatment has been recommended for U.S. approval, told investors last week there was a case for valuing it at more than $1 million per patient, although it has yet to set an actual price.



    However, the U.S. Institute for Clinical and Economic Review (ICER) said this week "at a placeholder price of $1,000,000, the high cost makes this unlikely to be a cost-effective intervention at commonly used cost-effectiveness thresholds".

    The ICER analysis did concede Luxturna was likely to be more cost-effective for younger patients.


    The expected U.S. approval of Luxturna by Jan. 12 is seen as kick-starting the sector, following disappointing sales of the first two gene therapies in Europe.


    More treatments based on fixing faulty genes using viruses to carry DNA into cells are coming from companies like Bluebird Bio, BioMarin, and Sangamo.


    Spark's Chief Financial Officer Stephen Webster said on Thursday that gene therapy was upending conventional thinking by offering a one-time cure, rather than years of repeat prescriptions, but health systems were struggling to keep pace.


    "Gene therapy creates an unusual conundrum because we are fitting a round peg in a square hole ... it's tough," he told a Jefferies healthcare conference in London.


    Spark would like to say "if it works, pay us, and if it stops working, stop paying us", Webster told the meeting.


    But for Luxturna, which cost some $400 million to develop, such an offer was impractical, given the mechanics of the U.S. system and a reluctance by big health plans to move away from upfront payments for rare disease drugs.


    Longer-term, pay-for-performance models could be adopted for hemophilia, where the benefits of one-time treatment can be weighed against the huge cost of regular infusions of blood-clotting factors, Webster said.


    A one-off treatment would slash the need for such expensive care. But there are also indirect costs and quality of life benefits - especially in a condition like blindness - that manufacturers argue should be recognized.


    Nightstar Therapeutics CEO David Fellows, whose company is also developing gene therapies for eye disorders, said calculating gene therapy's true value was not easy.


    "Trying to capture all this into some sort of price algorithm is very challenging. But we are trying to quantify the emotional impact, the caregiver impact, the effect on careers and so on," he told the conference.




    (Reporting by Ben Hirschler; editing by Alexander Smith)



    blindnesscost dilemmaDavid FellowsDNAgene therapyHealthcarehemophiliaInstitute for Clinical and Economic ReviewLuxturnaNightstar Therapeuticsprice tagSpark Therapeuticsspotlight
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok